Sanofi announced on August 4, 2026, that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age. This regulatory milestone expands the vaccine’s reach to help protect against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. Previously, MenQuadfi was approved in the European Union for use in individuals aged 12 months and older. The expanded indication addresses a critical public health need, as infants face high rates of mortality and severe long-term complications from the disease, which can progress from onset to death within 24 hours.

The approval follows a positive opinion adopted by the Committee for Medicinal Products for Human Use on June 25, 2026. It marks the completion of all pediatric post-licensure commitments linked to MenQuadfi’s initial marketing authorization, confirmed by the receipt of a Paediatric Investigation Plan compliance statement from the European Medicines Agency. This regulatory clearance provides healthcare professionals in the EU with an additional option for vaccinating infants against invasive meningococcal disease from as early as six weeks of age, aligning with routine infant immunization schedules.

Clinical Data and Safety Profile

The EU approval is underpinned by comprehensive data from the MET58 pivotal clinical study, which evaluated the immunogenicity, safety, and tolerability of MenQuadfi in infants from six weeks of age. The study included more than 6,000 infants across 11 countries and multiple immunization schedules. Federico Martinon-Torres, Pediatrician and Clinical Researcher at Hospital Clínico Universitario de Santiago in Spain and Principal Investigator of MET58, noted that the immunogenicity data for MenQuadfi in infants is robust and supports usage with confidence in the EU.

MenQuadfi demonstrates a safety profile comparable to other MenACWY vaccines currently licensed. In infants, the vaccine can be co-administered with combined diphtheria-tetanus-acellular pertussis (DTaP)-inactivated poliovirus (IPV)-hepatitis B (HepB)-Haemophilus influenzae type b (Hib) vaccine, rotavirus vaccine (live attenuated), and 10-valent pneumococcal conjugate vaccine (PCV10).

Approved Dosing Regimens

The new dose regimen for those starting vaccination from six weeks of age is aligned with standard EU immunization schedules. The approved dosing protocols are detailed below:

Public Health Impact

Invasive meningococcal disease carries a case fatality rate of approximately 10–15%, with up to 20% of survivors experiencing permanent complications such as limb amputation, hearing loss, and neurological damage. Although serogroup A is rarely reported in the EU, serogroups C, W, and Y remain responsible for a significant share of cases across Europe. Bogdana Coudsy, Global Head of Medical, Vaccines at Sanofi, stated that offering protection for the EU’s youngest children reflects the scientific rigor behind the work and provides healthcare providers with an additional option to protect infants from the early weeks of life. MenQuadfi is currently approved in the EU, US, and multiple other countries.

Sanofi India Limited has accepted the cessation of Nakul Verma as a member of its Senior Management Personnel (SMP), effective from the close of business hours on July 31, 2026. The change stems from Verma’s transition to another role within the broader Sanofi group, indicating an internal lateral move rather than a departure from the company ecosystem. This update ensures regulatory transparency regarding leadership changes at the listed entity.

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) on July 31, 2026. Haresh Vala, Company Secretary and Compliance Officer of Sanofi India Limited, signed the communication, confirming adherence to statutory reporting requirements.

Regulatory Framework

The notification aligns with Schedule III of the Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. These regulations mandate timely disclosure of any changes in senior management personnel to ensure market participants are informed of shifts in key decision-making roles.

Leadership Transition Details

Nakul Verma held the position of Public Affairs and Market Access-Head within the company’s senior management structure. His exit from this specific SMP designation does not imply a termination of employment with the Sanofi group but reflects a reassignment to a different capacity within the organization. Such internal transitions are common in large multinational corporations and typically aim to optimize resource allocation across different business units or geographic regions.

What the Numbers Show

While this filing involves personnel changes rather than financial metrics, the timing of the transition—effective July 31, 2026—coincides with the end of the fiscal year for many Indian entities. This suggests that the handover of responsibilities related to public affairs and market access will be completed before the commencement of the new fiscal cycle, ensuring continuity in stakeholder communications and market strategy execution during the critical period of annual reporting and strategic planning.